Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Data by

Global Data

25

Revenue 2014

Merck KGaA

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Merck KGaA's 2013 sales performance.

Merck, Pfizer get first OK for checkpoint inhibitor avelumab

Merck, Pfizer get first OK for checkpoint inhibitor avelumab

Merck, Pfizer get first OK for checkpoint inhibitor avelumab. FDA approval for rare skin cancer drug. ... There's now a fourth player in the PD-1/PD-L1 inhibitor market, after Merck KGaA and Pfizer won FDA approval for avelumab in a rare form of skin

Merck confirms sale of biosimilar division

Merck confirms sale of biosimilar division Merck confirms sale of biosimilar division. German pharma group is in 'advanced discussions' with potential buyers. ... Merck KGaA has confirmed it intends to sell off its biosimilar drugs division, and is in "advanced discussions" with potential buyers.

Can NICE deliver on its funding promises?

Can NICE deliver on its funding promises? Moreover, while no product has yet received a negative final decision, draft ‘no’s for Kadcyla, Adcetris and Erbitux will have put Roche, Takeda and Merck KGaA on notice.

Avelumab costs peg back profit at Merck KGaA

Avelumab costs peg back profit at Merck KGaA Avelumab costs peg back profit at Merck KGaA. Development of its immuno-oncology product is central to Merck's healthcare plans. ... Rising costs related to the development of immuno-oncology drug avelumab ate into Merck KGaA's operating profit in the

BMS appoints three independent directors

BMS appoints three independent directors Since beginning his pharmaceutical career 40 years ago, Emmens has served as president, chief executive officer and chairman of Vertex Pharma, chief executive and chairman at Shire, president of Merck ... s pharmaceutical division, and president and

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Global Data Data by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pulsar

THE SCIENCE BEHIND CREATIVE RESULTS When science meets art there's chemistry. We simply add passion, positivity and a human warmth....

Latest intelligence

Precision medicine and the changing role of the healthcare professional
The growth of precision medicine introduces a shift away from treating the population as a whole, to treating each patient as an individual. How does this change the role of...
How will Sustainability and Transformation Plans (STPs) change the NHS commissioning landscape?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, take a look at new commissioning structures and what they mean for pharma...
eyeforpharma Barcelona 2017 highlights: Industry at the brink of transformation
Hear what Anthill's delegates reported back from the biggest eyeforpharma Barcelona yet....

Infographics